Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
about
(-)-SCR1693 Protects against Memory Impairment and Hippocampal Damage in a Chronic Cerebral Hypoperfusion Rat ModelWeight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.The developing utility of zebrafish models for cognitive enhancers researchPhysostigmine for Alzheimer's disease.A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease.The safety and tolerability of donepezil in patients with Alzheimer's disease.Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity.Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease.An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3-CA1 synapses in the hippocampus of adult ratsClinically tested drugs for Alzheimer's disease.Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteersEfficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.Donepezil: a review.Donepezil: an update.Alzheimer's disease drug development in 2008 and beyond: problems and opportunitiesA rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotilityCholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.Current advances in transdermal delivery of drugs for Alzheimer's disease.A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Regulation of gastric electrical and mechanical activity by cholinesterases in mice.Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents
P2860
Q27334259-1ADD2D8D-E16A-4149-83DA-70591427E2EDQ30234535-A82FF0B1-24B3-4FD1-A124-0D209736600CQ30457705-C5E9D080-E2CF-4851-BD85-5CA9D3E83E37Q33423337-35D6FA47-6C4B-4221-99C0-1F699C5910FAQ34309353-AB99D080-C51A-4AD8-9A69-A37770136384Q34552035-23BCB7D3-45DC-471C-BF33-491A89C845A9Q34746698-5F817B2E-CC02-46BE-9466-BCE619E03301Q34940747-F5EE3588-7E26-4407-A473-44135A1DC83FQ34993154-097762EE-4560-4414-BEA9-676990985D4DQ35043462-F072C35C-39A9-497D-875F-68D83824CA04Q35164747-1F8E766A-6AF8-4CF0-B5D2-2BCC24EF531EQ35184995-30745A0B-E592-457F-AF67-E1154636739CQ35539649-0BAB20D3-C96E-4B96-9743-048C1200B42BQ36544994-11829A41-DAB6-4AAF-A334-F2E148F9F511Q36808057-DEB5F59F-48B9-4A84-B772-F008E575B19DQ36942970-D51FC0AC-B3A4-4F94-A8C1-F5D91C6EADAAQ36998823-DB94AA9C-2F84-4A25-A984-3FB1BDD439C2Q37325828-3D60711D-1A76-466A-9F79-BA915239CE47Q37337891-0164EF21-0CF9-4508-92B3-4EC8BCCD7570Q37490737-3D969CF2-7827-4A9A-8CDF-A4416D3D8DC8Q37997774-22E4CA97-EA7E-4FA0-91AD-F425861EEA8AQ38350602-3223549B-A93E-4402-9C01-EF7D75EBF3E9Q38657942-F8E69B91-1DB1-4CFC-8AA4-381F37C632EDQ38851564-8400A3F6-72B5-48AE-8CAD-61139B54517DQ39038234-EDDEC26C-DF49-456E-9D34-15561FDEC5D9Q39665491-F95E65AF-A7DF-454B-BD4C-C1C1A0964183Q43609548-57701AB5-3891-415F-9E73-20C68D047276Q44407158-61494BB7-2402-40C3-BBAE-340E8093E216Q46107336-AD991DFF-FA6D-45B3-8DBE-678811FDC02FQ46804778-2409BD77-2AA7-4633-B0BA-76EA71DF4927Q47801349-7667CE4B-833A-4443-92F3-EF8752656B6BQ51491144-FFD14A2A-8011-4349-B1FD-A7F8A3B41659Q58794595-3F425212-4D4D-4363-BFD0-7E47DD551637
P2860
Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@ast
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@en
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@nl
type
label
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@ast
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@en
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@nl
prefLabel
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@ast
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@en
Pharmacodynamic-tolerability r ...... itors for Alzheimer's disease.
@nl
P1433
P1476
Pharmacodynamic-tolerability r ...... bitors for Alzheimer's disease
@en
P2093
Imbimbo BP
P304
P356
10.2165/00023210-200115050-00004
P577
2001-01-01T00:00:00Z
P5875
P6179
1010410159